Pfizer CEO’s Job Is at Risk. A Shot of Discipline Could Help.
As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.
Pfizer: A Strong Product Pipeline Could Lead To Significant Upside
Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...
FiercePharma1d
Dupixent takes pharma DTC top spot as Pfizer's COVID drug Paxlovid makes a comeback
AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.
Pfizer: A 6% Yielding Ultra SWAN Bargain With Upside Potential
Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...
kffhealthnews1d
Out Of The Trash Bin: How Cobenfy’s Unusual Journey Could Change Pharma
Bristol Myers Squibb's schizophrenia drug, which received FDA approval last week, took a long and winding road to get there. Three decades ago, Eli Lilly developed the drug's forerunner, xanomeline, ...